148 related articles for article (PubMed ID: 34565745)
1. Can Treatment for Substance Use Disorder Prescribe the same Substance as that Used? The Case of Injectable Opioid Agonist Treatment.
Steel D; Tekin Ş
Kennedy Inst Ethics J; 2021; 31(3):271-301. PubMed ID: 34565745
[TBL] [Abstract][Full Text] [Related]
2. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
[TBL] [Abstract][Full Text] [Related]
3. Exploring Patients' Perceptions on Injectable Opioid Agonist Treatment: Influences on Treatment Initiation and Implications for Practice.
Friedmann Z; Binder A; Kinkel HT; Kühner C; Zsolnai A; Mick I
Eur Addict Res; 2024; 30(1):32-42. PubMed ID: 38104539
[TBL] [Abstract][Full Text] [Related]
4. Injectable opioid agonist treatment: An evolutionary concept analysis.
Haines M; O'Byrne P
Res Nurs Health; 2021 Aug; 44(4):664-671. PubMed ID: 33993526
[TBL] [Abstract][Full Text] [Related]
5. High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants.
Fox AD; Riback L; Perez-Correa A; Ohlendorf E; Ghiroli M; Behrends CN; López-Castro T
Subst Use Addctn J; 2024 Jan; 45(1):44-53. PubMed ID: 38258851
[TBL] [Abstract][Full Text] [Related]
6. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.
Fairbairn N; Ross J; Trew M; Meador K; Turnbull J; MacDonald S; Oviedo-Joekes E; Le Foll B; Goyer MÈ; Perreault M; Sutherland C
CMAJ; 2019 Sep; 191(38):E1049-E1056. PubMed ID: 31548191
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
Bansback N; Guh D; Oviedo-Joekes E; Brissette S; Harrison S; Janmohamed A; Krausz M; MacDonald S; Marsh DC; Schechter MT; Anis AH
Addiction; 2018 Jul; 113(7):1264-1273. PubMed ID: 29589873
[TBL] [Abstract][Full Text] [Related]
8. Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.
Bozinoff N; Tardelli VS; Rubin-Kahana DS; Le Foll B
Harm Reduct J; 2022 Oct; 19(1):113. PubMed ID: 36229831
[TBL] [Abstract][Full Text] [Related]
9. Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities.
Nielsen S; Sanfilippo P; Belackova V; Day C; Silins E; Lintzeris N; Bruno R; Grebely J; Lancaster K; Ali R; Bell J; Dietze P; Degenhardt L; Farrell M; Larance B
Addiction; 2021 Jun; 116(6):1482-1494. PubMed ID: 33067836
[TBL] [Abstract][Full Text] [Related]
10. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans.
Eydt E; Glegg S; Sutherland C; Meador K; Trew M; Perreault M; Goyer MÈ; Le Foll B; Turnbull J; Fairbairn N
CMAJ Open; 2021; 9(1):E115-E124. PubMed ID: 33622764
[TBL] [Abstract][Full Text] [Related]
11. Supervised injectable opioid agonist therapy in a supported housing setting for the treatment of severe opioid use disorder.
Brar R; Sutherland C; Nolan S
BMJ Case Rep; 2019 Aug; 12(7):. PubMed ID: 31371332
[TBL] [Abstract][Full Text] [Related]
12. Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series.
Brar R; Fairbairn N; Colizza K; Ryan A; Nolan S
J Addict Med; 2021 Apr; 15(2):163-166. PubMed ID: 32769776
[TBL] [Abstract][Full Text] [Related]
13. Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).
Dobischok S; Metcalfe R; Matzinger E; Palis H; Marchand K; Harrison S; MacDonald S; Byres D; Schechter M; Bansback N; Oviedo-Joekes E
Int J Drug Policy; 2023 Feb; 112():103948. PubMed ID: 36586152
[TBL] [Abstract][Full Text] [Related]
14. HIV Treatment Initiation and Retention Among Individuals Initiated on Injectable Opioid Agonist Therapy for Severe Opioid Use Disorder: A Case Series.
Giang V; Brar R; Sutherland C; Nolan S
J Addict Med; 2020; 14(5):437-440. PubMed ID: 32011407
[TBL] [Abstract][Full Text] [Related]
15. Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment.
Marchand K; Foreman J; MacDonald S; Harrison S; Schechter MT; Oviedo-Joekes E
Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):7. PubMed ID: 31959189
[TBL] [Abstract][Full Text] [Related]
16. Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report.
Palis H; MacDonald S; Jun J; Oviedo-Joekes E
Harm Reduct J; 2021 May; 18(1):57. PubMed ID: 34016137
[TBL] [Abstract][Full Text] [Related]
17. Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series.
Patricelli CJ; Chai J; Gordon S; Gouin IJ; Carter N; Stewart K; Paquette V; Urbanoski K; Albert A
J Addict Med; 2023 Jul-Aug 01; 17(4):431-438. PubMed ID: 37579103
[TBL] [Abstract][Full Text] [Related]
18. Eligibility for heroin-assisted treatment (HAT) among people who inject opioids and are living with HIV in a Canadian setting.
Klimas J; Dong H; Fairbairn N; Socías E; Barrios R; Wood E; Kerr T; Montaner J; Milloy MJ
Addict Sci Clin Pract; 2018 Feb; 13(1):3. PubMed ID: 29409539
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.
Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT
Drug Alcohol Rev; 2018 Jan; 37(1):137-146. PubMed ID: 28593748
[TBL] [Abstract][Full Text] [Related]
20. Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities.
Friedmann Z; Kinkel HT; Kühner C; Zsolnai A; Mick I; Binder A
Harm Reduct J; 2023 Nov; 20(1):162. PubMed ID: 37915058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
